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Abstract
Background: Psychotic disorder due to methamphetamine has a high prevalence with an unknown nature and history. Patients
with such disorders are faced with the risk of recurrence of abuse and other psychiatric disorders. Methamphetamine-induced
psychotic disorders may continue by independent of methamphetamine abuse, such as primary psychotic disorders (such as
schizophrenia).
Objectives: This study was performed to evaluate the mental health and frequency of methamphetamine-induced psychosis in
patients referred to Iran psychiatric hospital (a university hospital in Tehran, Iran).
Patients and Methods: The research was done on patients with methamphetamine-induced psychosis after 2 to 5 years using of
methamphetamine (150 person in the Iran Psychiatric Hospital) .The diagnostic interview was done based on a semi-structured
interview (SCID). The data was analyzed by Binary Logistic Regression Model.
Results: From 150 patients that were followed, 6 of them (4.0%) died during the phone interview-follow up. The mean age of alive
patients was 34.9± 8.7 years and 12 of them were women (8.0%). At the follow-up interview, 38 patients reclassified as the cases of
schizophrenia (25.3%), 17 as the cases of major depressive disorder (11.3%), 7 as the cases of bipolar disorder type I (4.7), two as the cases
of schizoaffective disorder (1.3%), and two of them as the cases of delusional disorder (1.3%). A total of 84 cases (56.0%) were diagnosed
as recovered cases or as methamphetamine-induced psychotic disorders. Prediction of diagnosis change showed the diagnosis of
methamphetamine use disorder (adjusted OR = 3.978, 95% CI: 1.265 - 12.512), previous psychiatric admission (adjusted OR = 6.749; 95%
CI: 1.639 - 27.779), and short duration of psychotic episode (adjusted OR = 0.171; 95% CI: 0.056 - 0.520.
Conclusions: The results of our study show that methamphetamine-induced psychotic disorders are associated, in many cases,
with the mood disorders. It seems that comorbid mood disorders, age of first use, history of previous psychiatric hospitalization,
the risk of methamphetamine use disorders, and psychotic episodes are associated longer with the diagnosis towards primary psy-
chotic disorders.
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1. Background
For years, stimulants were selling as a licensed and pre-
scribed drug in different countries due to being known as
effective in increasing alertness, reducing fatigue, insom-
nia, loss of appetite, and creating a sense of well being (1).
The prevalence of amphetamine dependence is increasing
in the world, according to the relevant unit of the united
nations (UNODC). After marijuana, methamphetamine is
currently the second most common substance of abuse
around the world (2). In Iran, illegal use of stimulants has
increased dramatically in recent years (2, 3).
Several studies have shown the association between
methamphetamine use and similar compounds to occur
in acute psychosis. Methamphetamine may lead to very
similar psychotic symptoms of schizophrenia spectrum,
which is why it is difficult to make differential diagnosis
(4). Recent studies have shown that up to 25% of those who
were initially diagnosed with methamphetamine-induced
psychosis, were later diagnosed with early psychotic disor-
der (1).
Akiyama et al. in Japan, conducted a study on metham-
phetamine abuse by 32 female subjects (5) with the aver-
age abuse duration of 2 to 30 years and 5 to 31 months
after cessation by injection. These females were suffer-
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ing from psychosis as in 9 patients, recurrence had also
occurred in no abuse of methamphetamine. The most
common symptoms include: psychosis (auditory halluci-
nations, delusions), violence, delirium, depression, and
suicidal ideation. Furthermore, in a significant propor-
tion of patients, depressive symptoms persisted for several
months after treatment with anti-psychotics.
In another study regarding long-term consequences of
methamphetamine abuse after the first hospitalization in
Thailand by Kittirattanapaiboon et al. it was shown that
50.7% of the patients had a psychotic relapse and 22.3%
had attempted suicide. The results of this study indicated
that many people with methamphetamine psychosis have
a poor prognosis and most of them suffer from prema-
ture death, recurrence of psychotic symptoms, prolonged
psychosis, high rates of alcohol abuse, and suicide, which
makes it necessary to follow them with more accurate and
frequent visits (6). Other studies emphasize the psychotic
disorder after methamphetamine use (7-12).
Due to results of a large study that was conducted dur-
ing 1987 and 2003 in Finland, in most of the cases, the di-
agnosis had occurred during the first three years of the
follow-up (13).
2. Objectives
This study, were inspired to review and to examine the
clinical status and mental health of patients hospitalized
in the Iran Psychiatric Hospital with a diagnosis of psy-
chotic disorder caused by methamphetamine after 2 to 5
years, from 2007 to 2011.
3. Patients and Methods
This study is a retrospective cross-sectional study. The
population of the study consisted of patients with psy-
chotic disorders caused by methamphetamine use admit-
ted to the Iran psychiatric hospital during the period of
2007 to 2011.
Due to the risk of sample loss because of the cases’ un-
availability, impossibility of interview caused by physical
and psychological limitations, death of subject (s), or un-
willingness to participate in the interview, about 2 times
of the total number (324 persons) of all patients hospi-
talized from 2007 onwards, in the Iran Psychiatric Hospi-
tal, due to aforementioned problems with at least 2 years
past their initial admission, were randomly selected and
received a phone call, which resulted in 150 people who
were available and gave their verbal consent to participate
in research.
The inclusion criteria included the admission with
a diagnosis of psychotic disorder caused by metham-
phetamine abuse, the diagnosis should be confirmed by a
psychiatrist who is a faculty member at the time, an avail-
able landline, Persian dialect, and verbal or written con-
sent to participate in research.
The exclusion criteria included the patient’s unwilling-
ness to cooperate in the project or in the absence of suffi-
cient information and unwillingness of the patient regard-
ing interviewing their families.
If the person did not cooperate during the calls, or it
was not possible to interview him/her after several calls,
he/she was removed from the watch list. In cases that the
information regarding the patient’s history was different
from the file information, the results of the questionnaire
would be applied. During the call, the patient was asked
to announce his/her desire regarding participation in this
research study.
The patient was encouraged to participate in the study
by receiving free visits and copies and free consultation by
calling the psychiatry resident. If it was not possible to visit
the patient personally, a patient questionnaire would be
completed by phone interview. Two psychiatric residents
conducted and coordinated the interviews and three men
were jointly interviewed; then, the diagnostic matching
was performed. The diagnostic interview was done based
on the SCID field of psychotic disorders, mood episodes dis-
orders, alcohol dependence, and other disorders. The SCID
is a semi-structured interview, which provides diagnoses
based on the DSM-IV-TR. According to the study conducted
in Iran by Eghtedari et al. (13), the SCID had acceptable reli-
ability of the Iranian version and the total Kapa for all cur-
rent diagnosis was 0.52 and the diagnosis for the entire life-
time was 0.55.
4. Results
4.1. Demographic Data
In the study, 150 patients were followed. A total of 6
of them (4.0%) died during the phone call follow-up. The
mean age of individuals who were alive was 34.9 years (SD:
8.7). The median age was 33 years with a range of 21 to 61
years. A total of 41 patients (28.5%) were under 30 years old
(Table 1). Only 12 women (8.0%) were present in this group.
All the women were housewives and the total of 99 patients
(68.9%) were considered unemployed. Demographic pro-
file of the patients is shown in Table 1. It is necessary to no-
tice that the demographic data of dead patients belong to
the follow-up period.
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Table 1. Demographic Characteristics of Patients Who Re-Evaluated After First Diag-
nosis of Methamphetamine-Induced Psychotic Disordera
No. (%)
Sex
Male 138 (92.0)
Female 12 (8.0)
Marital status
Single 75 (50.0)
Married 52 (34.7)
Divorced or Widow 23 (15.3)
Occupation
Jobless (males) 92 (61.3)
Housewives 12 (8.0)
Employee 46 (30.7)
Education
Illiterate 6 (4.0)
Low level 84 (56.0)
High school diploma 57 (38.0)
University degree 3 (2.0)
aIn deceased ones the last status was considered.
4.2. Methamphetamine Use
According to DSM-IV-TR and current (or the last) situa-
tion of methamphetamine use, 19 individuals (12.7%) were
diagnosed as a methamphetamine abuser and 60 (40.0%)
as methamphetamine dependent.
The mean age of onset of methamphetamine use in
these patients was 28.8 years (SD: 7.7) and in the range of
13 to 53 years (median: 28 years). A total of 12 individu-
als (8.0%) began methamphetamine use before the age of
20, 16 of them (10.7%) had started it after entering the fifth
decade of their life (Table 2).
A total of 27 individuals (18.0%) had a history of pre-
vious psychiatric hospitalization and 81 patients (54.0%)
were re-admitted in psychiatric wards after index hospital-
ization. The maximum readmission times was 8. After the
first period of hospitalization, due to methamphetamine-
induced psychotic disorder, 95 (63.3%) had a recurrence
of psychosis with or without methamphetamine use. Du-
ration of a psychotic period of first hospitalization var-
ied from 1 to 120 days (median: 4 days). The median
time between the first use of methamphetamine and
methamphetamine-induced psychotic disorders was 5
months (range: 0.5 to 72 months). Also, 28 patients (18.7%),
after the first episode of methamphetamine-induced psy-
chotic disorder, were intoxicated with methamphetamine
at least once (Table 2).
Table 2. Distribution of Variables Associated with Methamphetamine Use Among
150 Patients Previous Diagnosis of Methamphetamine-Induced Psychotic Disorder
No. (%)
Diagnosis of methamphetamine use disorder
Abuse or dependence 79 (52.7)
Previous hospitalization in psychiatric ward
Yes 27 (18.0)
History of suicide attempt
No 123 (82.0)
Once 10 (6.7)
Two or more 17 (11.3)
Relapse of psychosis
Yes 95 (63.3)
Re-hospitalization
No 69 (46.0)
Once or twice 69 (46.0)
Three times or more 12 (8.0)
History of methamphetamine intoxication
Yes 23 (15.3)
First use of methamphetamine, decade
2nd 12 (8.0)
3rd or 4th 122 (81.3)
5th or 6th 16 (10.7)
Time interval between first use and incidence of psychosis,
mo
less than 3 47 (31.3)
3.0 - 5.5 33 (22.0)
6.0 - 12.0 40 (26.7)
More than 12 30 (20.0)
Duration of the index psychotic episode, d
Less than 7 94 (62.7)
7 - 29 46 (30.7)
≥ 30 10 (6.7)
4.3. Other substance Use
The most common substance used by these patients
was nicotine (dependence rate of 76.7%). Other substances
used by substantial portion of the patients were nicotine,
cannabis, and opioids (82.0%, 26.7% and 22.0%, respectively;
Table 3).
4.4. History of Suicide
A total of 27 patients (18.0%) had attempted suicide dur-
ing the follow-up period. Among them, 18 subjects (12.0%)
had attempted once or twice, and the others at least three
time (maximum: 8 times).
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Table 3. Frequency of Current Substance Use Disorders Among 150 Patients with Previous Diagnosis of Methamphetamine-Induced Psychotic Disorder
No Use Use Abuse Dependence
Methamphetamine 71 (47.3) - 19 (12.7) 60 (40.0)
Nicotine 27 (18.0) 8 (5.3) - 115 (76.7)
Cannabis 110 (73.3) 8 (5.3) 27 (18.0) 5 (3.3)
Opioids 117 (78.0) 5 (3.3) 14 (9.3) 14 (9.3)
Ecstasy 145 (96.7) 4 (2.7) 1 (0.7) -
Hallucinogens 148 (98.7) - 2 (1.3) -
Other substances 129 (86.0) 8 (5.3) 11 (7.3) 2 (1.3)
4.5. Mortality
Despite insufficient information on the causes of death
of 6 patients and unwillingness of families to talk about it,
the following information was obtained:
Patient 1: 28-years-old, died apparently due to a heart
attack.
Patient 2: 26-year-old died due to suicide by consuming
opium.
Patient 3: 40-years-old died in a hospital a month later
due to heart attack resulting from concomitant use of
drugs (opium and methamphetamine) and drugs.
Patient 4: Died at the age of 34, in the camp, and as
a result of drug use. The patient suffered from severe de-
pression and potential suicide attempt, which resulted in
death.
Patient 5: Died at the age of 41 of a heart attack. The
dead patient was reported suffering from psychosis, de-
spite not using glass in last 3 to 4 years.
Patient 6: Died at age 32, due to poisoning with
methamphetamine, according to a forensic report.
4.6. Re-Diagnosis
At the follow-up interview, 38 patients reclassified as
the cases of schizophrenia (25.3%), 17 as the cases of ma-
jor depressive disorder (11.3%), 7 as the cases of bipolar
disorder type I (4.7), two as the cases of schizoaffective
disorder (1.3%), and two as cases as delusional disorder
(1.3%). A total of 84 cases (56.0%) were diagnosed as re-
covered cases or as methamphetamine-induced psychotic
disorder. Excluding deceased individuals, to predict diag-
nosis change from methamphetamine-induced psychotic
disorder to other major psychiatric disorders (including
schizophrenia, schizoaffective disorder, delusional disor-
der, major depressive disorder and bipolar disorder type
I), we used binary logistic regression model. In this model,
predicting variables were age (< 30 years and≥ 30 years),
sex, first age of methamphetamine usage (< 20 years and
≥ 20 years), diagnosis of methamphetamine use disorder
(including abuse or dependence), previous admission (be-
fore index admission), short duration of psychotic episode
in index admission (less than 7 days), prolonged psychotic
period in index admission (≥ 30 days), interval between
first use of methamphetamine and first psychotic episode
(< 6 months and ≥ 6 months), and major mood disor-
der comorbidity. In this model Cox & Snell R2 was 0.507
(P < 0.001). By using this regression model we can cor-
rectly classify patients as the cases of final diagnosis of
methamphetamine-induced psychotic disorder (diagno-
sis not changed over time) in 72 out of 82 cases (87.8%)
or other major psychiatric disorder in 53 out of 62 cases
(85.5%). Based on the binary regression model, variables
that may help predicting diagnosis change are diagnosis of
methamphetamine use disorder (adjusted OR = 3.978, 95%
CI: 1.265 - 12.512), previous psychiatric admission (adjusted
OR = 6.749; 95% CI: 1.639 - 27.779), and short duration of psy-
chotic episode (adjusted OR = 0.171; 95% CI: 0.056 - 0.520.
The results are shown in Table 4.
5. Discussion
The aim of this study was to evaluate the mental health
of those admitted with a diagnosis of psychotic disorder
caused by methamphetamine abuse in the Iran psychi-
atric hospital during a time period of 2 to 5 years. The
mean age of the participants in this study was 34.9 years
(SD: 8.7), which is more than the mean age of 30 patients
with a methamphetamine abuse admitted in the Iran psy-
chiatric hospital in 2012 whose cognitive functions were
examined. In that study, the average age of the patients
suffering from methamphetamine psychosis was 32.1 (13).
On the other hand, based on the studies done outside of
Iran such as a study on 248 individuals diagnosed with
methamphetamine abuse in 2014, the average age of the
first methamphetamine intake was 17.8 years (14). This
could indicate that the use of methamphetamine amongst
young people is more frequent than others, which could
lead to irreparable consequences for social performance.
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Table 4. Results of Binary Logistic Regression Model to Predict Diagnosis Change Over Time from Methamphetamine-Use Disorder to Other Major Psychiatric Disorders
Variable B± SE Wald P Value Adjusted OR 95% CI for Adjusted OR
Age, y (≥ 30) -0.26± 0.65 0.15 0.696 0.76 0.22 - 2.79
Sex (female) -17.792± 5651.94 0.000 0.997 0.000 -
Methamphetamine use disorder 1.38± 0.59 5.58 0.018 3.98 1.27 - 12.51
Age at first use of methamphetamine, y (< 20) 0.13± 0.51 0.06 0.81 1.133 0.42 - 3.07
Previous admission in psychiatric ward 1.91± 0.72 7.00 0.008 6.75 1.64 - 27.78
Short duration of psychotic episode, d (< 7) -1.77± 0.57 9.68 0.002 0.17 0.06 - 0.52
Prolonged duration of psychotic episode, d (≥ 30) 0.34± 1.00 0.12 0.75 1.41 0.20 - 10.07
Interval between first use and incidence of psychosis, mo (≥ 6) -0.42± 0.56 0.56 0.45 0.66 0.22 - 1.97
Mood comorbidity 37.33± 8288.43 0.000 0.996 1.6× 1016 -
Abbreviations: CI, confidence interval; OR, odds ratio.
The results of this study showed that 44.4% of par-
ticipants (559 patients) has at least once used metham-
phetamine during their life. In our study, the prevalence of
methamphetamine abuse was 12.7% and the dependence
frequency was 40.0%, which is close to the results of the
above-mentioned study. Comparing the results of both
studies’ high percentage of methamphetamine, users may
experience side effects such as psychosis.
Results of our study also indicated that 18.0% of par-
ticipants had a history of previous psychiatric hospitaliza-
tions and more than half of them (54.0%) have again been
hospitalized in psychiatric wards at the time of this re-
search.
In a study on 744 retired members of the U.S. military
with methamphetamine abuse, the results showed that
23.4% of the users have been readmitted to the hospital
and 13.1% of them have been hospitalized more than three
times (15). Although the methodology of this study is dif-
ferent from the previously mentioned, it is important to
note that people with psychosis due to methamphetamine
abuse, compared to consumers without symptoms, are in
need of readmission with a higher percent. However, re-
sults of this study revealed that 18.7% of patients, after the
first methamphetamine-induced psychosis, were at least
once poisoned with it.
It can be concluded from our study that 63.3% of sub-
jects faced with relapse of psychosis after the first admis-
sion, which had an average duration of 30 days. In a
study by Fasihpour et al. on 111 hospitalized patients with
methamphetamine induced psychosis, the results showed
that the mean duration of hospitalization was 21.43 days
and the mean duration of episodes of psychosis lasted 17.37
days (4), which is nearly close to the results of our study.
According to the study by Ujik et al. methamphetamine
abuse has three main features, which included progressive
qualitative change in psychological symptoms from lack
of psychosis to progressive psychosis, also, patients with
methamphetamine abuse vulnerability to psychotic re-
lapse has increased and in case of re-taking, this vulnerabil-
ity will last for a very long time. These characteristics were
named as the sensitivity of methamphetamine abuse and
can explain the recurrence of methamphetamine-induced
psychosis by stress and prolonged intractable psychosis
caused by methamphetamine (16).
In a study by Akiyama et al. in Japan, conducted on 32
female abusers of methamphetamine, it was shown that
the mean duration of abuse was found to be 2 to 30 years
where psychosis had arisen during 5 to 31 months after
cessation of methamphetamine injection and 9 patients
had a recurrence in the absence of methamphetamine
abuse. In addition, a significant number of patients with
the above symptoms were suffering from depression for
some months after treatment with anti-psychotics. The
results of this study signify that in people who have less
comorbidity with other psychiatric disorders, metham-
phetamine psychosis has a better prognosis. Also, in this
study, it was concluded that the symptoms of psychotic
and mood symptoms could be important in both recur-
rence and prognosis of patients with methamphetamine
abuse (5). On the other hand, due to the high comorbid-
ity of depressive symptoms in people who abuse metham-
phetamine, it is hypothesized that the risk of other psy-
chiatric disorders may underlie addiction or relapse of
methamphetamine use (17).
The results showed that 18.7% of those surveyed had
attempted suicide during their follow-up. In a study con-
ducted in Thailand, long-term consequences of metham-
phetamine abuse in patients who were evaluated after the
first hospitalization was examined. In this study, 1,116 pa-
tients were examined after seven years of follow ups and
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results showed that 8.2% of them had died due to suicide,
accidents, and AIDS; 39.2% were readmitted and 38% were
diagnosed with schizophrenia caused by prolonged psy-
chosis. The results of this study showed that many peo-
ple with psychosis induced by methamphetamine had a
poor prognosis, most of them being affected with early
death, frequent recurrence of psychotic symptoms, pro-
longed psychosis, high rates of alcohol abuse, and suicide,
which makes it necessary to more accurate and frequent
visits (6). Comparing the results of this study with the cur-
rent one shows that the suicide rate is lower in our study,
which can be due to cultural differences with Thailand, re-
luctance on part of patients participating in the study to
mention about their past suicide attempts or lack of long-
term follow-ups of patients in our study.
On the other hand during the follow-ups in our study,
seven patients had died due to cardiac arrest with four
cases of heart failure, two cases of suicide, and one case
of acute methamphetamine intoxication. Thus, the main
cause of mortality in this study was cardiovascular inci-
dents, which is different from the results of study con-
ducted in Thailand, where the main cause of death was
suicide. The mortality statistics in methamphetamine
abusers in the current study was 4.0%, which is lower than
Thailand (8.2%).
This emphasizes the importance of cardiovascular
complications caused by the methamphetamine compo-
nents in Iran, which necessitates further studies.
A study by Moon et al. in 2014, showed that people
who abuse methamphetamine have been hospitalized due
to cerebrovascular accidents during a 1 to 3 year follow-up
with significantly worse prognosis than those who did not
use methamphetamine (18).
On the other hand, the results of previous studies em-
phasized that the use of methamphetamine has increased
the risk of cardiomyopathy as well as cardiovascular events
and is also associated with increased risk of sudden death
(19).
The lower suicide rate in Iran may be due to cultural
differences or other factors of methamphetamine users
where further studies are needed for an answer.
In our study, prediction of diagnosis change showed
the diagnosis of methamphetamine use disorder (ad-
justed OR = 3.978, 95% CI: 1.265 - 12.512), previous psychiatric
admission (adjusted OR = 6.749; 95% CI: 1.639 - 27.779), and
short duration of psychotic episode (adjusted OR = 0.171;
95% CI: 0.056 - 0.520.)
During 1987 to 2003, a large study of 18,478 patients,
who were first diagnosed with psychosis of material and
had been hospitalized, was conducted in Finland. Dur-
ing the study, patients were followed for either the on-
set of psychotic symptoms or death, to reach the stud-
ies end (whichever occurred first), and their psychiatric
changes were examined. In many cases, the diagnosis
of psychosis induced by methamphetamine was changed
to schizophrenia, which was more common in men than
women. More diagnosis changes occurred during the
first three years of follow-up. Therefore, it seems that
methamphetamine-induced psychosis is a significant pre-
dictor of establishing the diagnosis of schizophrenia spec-
trum disorders in the future (20) and the results of this
study also confirm this point.
A study on 295 patients who abuse methamphetamine
was conducted in Canada where the patients were fol-
lowed for 6 months on a monthly basis. The most power-
ful predictors of persistent psychotic symptoms inside the
study were more severe psychotic symptoms, persistent
period of abuse, and depression. These results indicate the
importance of co-morbidities in persistence of psychosis
induced by methamphetamine use (10). In the current
study, lack of diagnosis was associated with stronger prob-
abilities of mood comorbidities as well.
A study was conducted in 2013 in Malaysia where 292
patients who had a diagnosis of dependence on metham-
phetamine were examined. In the meantime, 13% of the
patients’ were psychotic at the time of the study and 48%
had a history of psychotic symptoms. The study found
that there is a significant association between psychosis
induced by methamphetamine use and major lifetime de-
pressive disorder (OR = 7), bipolar disorder (OR = 14), and
antisocial personality disorder (OR = 12.5). In addition,
heavy methamphetamine use was associated with the in-
cidence of induced psychosis (9).
A study of 80 Japanese female patients in 2011 showed
that despite long-term abstinence, a subgroup of metham-
phetamine consumers was aﬄicted with chronic psy-
chosis. It was also found that mood symptoms were effec-
tive on the severity of people’s psychosis (5).
In another study on 744 cases of retired military
methamphetamine abusers, it was concluded that the
most common psychiatric disorders included mood disor-
ders, psychotic disorder, and post-traumatic stress (21).
In a study conducted in South Africa, 235 patients with
methamphetamine abuse were examined; 59% of them
were affected with delusions and 57% had hallucinations.
Amongst them, 74% suffered from some kind of aggres-
sion. From 235 participants, 41% received a final diagno-
sis of methamphetamine use. In addition, during a 5-year
follow-up study 31% of subjects received final diagnosis of
schizophrenia and 12% of them were eventually diagnosed
with bipolar disorder. The results of this study showed that
mood disorders were more common in women than men
(22).
As it shows, the detection of early psychosis and psy-
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chosis induced by methamphetamine is difficult based
on the acute symptoms. Although it seems that recovery
from methamphetamine-induced psychosis is faster com-
pared with psychosis schizophrenia, the symptoms com-
pletely disappear. In both schizophrenia spectrum disor-
ders and methamphetamine-induced psychosis, there are
some predisposing genes. People that carry these genes
probably have a lower psychotic symptom threshold and
they suffer from less favorable clinical conditions (21).
Thus, there is a complex relationship between the use
of amphetamines and psychosis, which is not completely
discovered yet.
5.1. Study Limitations
The background variables belong to the time of the
follow-up and they were not considered during the first
admission, which can put a negative impact on the demo-
graphic result interpretation and people’s current status.
The persons age or cause of death is not clear, given the im-
portance of the cause of death in patients with metham-
phetamine use, information indicated seems necessary.
5.2. Conclusions
The results of our study showed that
methamphetamine-induced psychosis can be associated
with other psychiatric disorders. In addition, noticing the
disorders and curing them can prevent further complica-
tions of these comorbidities. Although the study cannot
say exactly whether other disorders existed at the start of
hospitalization, simultaneously occurred with psychotic
induced by methamphetamine, or during the recovery of
the early psychosis symptoms, this is clear that many peo-
ple suffering from methamphetamine psychosis will be
affected with recurrence of methamphetamine psychosis
symptoms with or without taking methamphetamine,
which emphasizes on the importance of these patients’
follow-up after discharge.
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